You are a key healthcare player, who develops and/or markets medicines, vaccines, medical devices or in-vitro diagnostics.
You are looking for a provider able to optimise the value of your products to health authorities and other decision makers, in order to maximize their reimbursement level.
stève consultants is a consulting specialist in Market Access and HEOR studies. Our qualified consultants, our network and our human approach focusing on deliverables quality and timelines compliance makes our company a key player in France since 2006.
years of experience
Stève Bénard – Executive Director
Josselin Boussel, Head of Market access
of stève consultants since 2010
For more than 10 years, stève consultants has been specialized in:
- strategic consulting for pricing & reimbursement,
- developing arguments and estimating target populations,
- writing of reimbursement dossiers for French health authorities (transparency, CNEDiMTS and economic dossiers).
Our bonus: Working closely with you through evaluations by the French National Authority for Health (HAS) as well as through pricing negotiations with the French Economic Committee of Healthcare Products (CEPS).
Our dedicated consultants conceive and develop:
health economic evaluations for health authorities (efficiency evaluation for the French Economic Committee of Evaluations in Public Health (CEESP), pricing negotiations with the CEPS…)
simulation tools to serve the medico-marketing strategy
budget impact model
epidemiology and clinical inputs
Our bonus: Strategic and technical guidance alongside the project.
Fanny Porte, HEOR Consultant
Charlotte Cancalon, Health-economist statistician
of stève consultants since 2009
stève consultants realises your observational studies from databases, notably claims ones (PMSI, EGB, SNIIRAM):
post-inscription studies required by health authorities,
ad-hoc pharmaco-epidemiological, epidemiological or health-economic studies to sustain your Market access strategy
Our bonus: Support of a dedicated scientific steering committee / possible cross with clinical registries or physicians’ panels.